# A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

> **NCT02411448** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 545 (actual)

## Conditions studied

- Metastatic Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Placebo
- **DRUG:** Erlotinib
- **DRUG:** Gefitinib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT02411448
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-05-06
- **Primary completion:** 2019-01-23
- **Final completion:** 2026-12
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02411448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02411448, "A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02411448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*